Retatrutide (LY3437943) is a synthetic triple receptor agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) simultaneously. Developed by Eli Lilly, it represents the next generation of incretin-based metabolic research compounds, extending the dual GLP-1R/GIPR agonism of Tirzepatide with the addition of glucagon receptor activity. Phase II clinical trial data published in 2023 showed some of the largest weight reduction signals recorded for any pharmacological compound to date, placing Retatrutide among the most actively investigated compounds in obesity and metabolic disease research.
For researchers examining incretin receptor biology, the mechanistic basis of body weight regulation, or the comparative pharmacology of GLP-1R-based compounds, Retatrutide offers a uniquely characterized tri-agonist research tool with a growing clinical evidence base and an active Phase III development program.
Retatrutide is a long-acting peptide engineered to co-activate three receptors — GLP-1R, GIPR, and GCGR — through a single molecular entity. The compound is based on a GIP analog backbone modified to incorporate GLP-1 and glucagon receptor activity, with a fatty acid chain enabling albumin binding and the extended half-life (~6 days in humans) required for once-weekly subcutaneous dosing in clinical research designs.
The incorporation of GCGR agonism distinguishes Retatrutide from earlier dual agonists. Glucagon receptor activation promotes hepatic glucose output and fat oxidation — effects that were historically considered undesirable in metabolic therapies. Research with Retatrutide has provided evidence that GCGR agonism, when balanced against GLP-1R and GIPR activity, can enhance weight reduction and fat-specific energy expenditure without producing net hyperglycemic effects, because the GLP-1R-mediated insulin secretion and GIP-mediated insulinotropic activity counteract glucagon’s glycemic effects while preserving its lipolytic and thermogenic properties.
The compound is supplied as a lyophilized powder that reconstitutes in aqueous vehicle. Its fatty acid modification and large molecular size (~4,748 g/mol) require careful handling and storage conditions consistent with other long-acting GLP-1R-based research peptides.
| Property | Value |
|---|---|
| Full name | Retatrutide (LY3437943) |
| Also known as | LY3437943, Eli Lilly GIP/GLP-1/glucagon tri-agonist |
| Receptor targets | GLP-1R, GIPR, GCGR (triple agonist) |
| Molecular weight | ~4,748 g/mol |
| CAS number | 2381719-04-4 |
| Purity (Official Peptides) | >99% by HPLC |
| Physical form | White lyophilized powder |
| Solubility | Water soluble (aqueous buffer) |
| Half-life (clinical data) | ~6 days (enables once-weekly dosing) |
| Storage (lyophilized) | 2–8°C, protected from light and moisture |
| Storage (reconstituted) | 4°C, use within 30 days |
Retatrutide’s most prominent research profile concerns its effects on body weight in clinical trial settings. Phase II data from the GZGI trial (NCT04881760), published in The New England Journal of Medicine in 2023, documented mean weight reductions of 17.5% at the 8mg dose and 24.2% at the 12mg dose over 48 weeks in adults with obesity and without type 2 diabetes. These magnitudes exceeded weight reduction signals reported at comparable timepoints for both semaglutide (GLP-1R monoagonist) and Tirzepatide (dual GLP-1R/GIPR agonist) in their respective Phase II trials.
Researchers attribute the enhanced weight reduction profile to the additive contribution of GCGR agonism, which promotes hepatic fat oxidation and may increase energy expenditure through thermogenic mechanisms. Body composition analysis from the Phase II trial indicated that weight reduction was predominantly from fat mass, with lean mass preservation — a finding consistent with the anabolic effects of GIP receptor activation counterbalancing the potential lean mass-reducing effects of aggressive caloric deficit.
The dose-dependent weight reduction observed with Retatrutide, and the apparent lack of a clear plateau at the highest doses studied, has attracted significant research attention as evidence that GCGR co-agonism may remove a ceiling effect that limits GLP-1R-only approaches to weight management.
Phase II research examining Retatrutide in subjects with type 2 diabetes and obesity documented significant reductions in HbA1c alongside weight reduction, consistent with the well-established glycemic benefits of GLP-1R agonism. The concern that GCGR agonism — which promotes hepatic gluconeogenesis — would compromise glycemic control was not borne out in trial data, where the balance of GLP-1R-mediated insulin secretion and GIPR-mediated insulinotropic activity offset glucagon receptor-driven glucose output.
Research examining Retatrutide’s glycemic mechanism relative to Tirzepatide has noted that GCGR agonism introduces a gluconeogenic pressure that must be overcome by the incretin components — a pharmacodynamic balance with implications for understanding glucose homeostasis and for selecting appropriate patient populations in future research designs. Fasting glucose changes have been closely monitored in Retatrutide research as the primary indicator of whether the glucagon component disrupts overall glycemic control.
Glucagon receptor agonism has well-established effects on hepatic lipid metabolism — including stimulation of fatty acid oxidation, reduction of lipogenesis, and promotion of ketogenesis. Research has examined whether Retatrutide’s GCGR component produces measurable effects on hepatic fat content and lipid profiles that go beyond what is achievable with GLP-1R monoagonists or dual GLP-1R/GIPR agonists.
Early research data has documented improvements in liver fat content measured by MRI-PDFF in Retatrutide-treated subjects, alongside favorable lipid profile changes including reductions in triglycerides and LDL cholesterol. These hepatic effects are of particular research interest in the context of non-alcoholic fatty liver disease (NAFLD/MASH), where glucagon receptor biology represents a distinct mechanistic target from the incretin pathways alone.
The cardiovascular effects of GLP-1R agonism have been extensively documented in large outcomes trials for semaglutide and other compounds in the class. Retatrutide’s cardiovascular research profile is currently defined by its Phase II data showing favorable effects on blood pressure, heart rate, and lipid parameters, alongside the ongoing Phase III cardiovascular outcomes trial.
Research has noted that GCGR agonism produces modest increases in heart rate — an effect also associated with GLP-1R agonism — and research designs examining cardiovascular endpoints in Retatrutide models must account for this hemodynamic effect when interpreting cardiac outcomes data. The net cardiovascular effect of triple receptor agonism, integrating the vasodilatory GLP-1R effects, the lipid-modulating GIP effects, and the hepatic GCGR effects, remains an active area of investigation.
Research examining Retatrutide in the context of the evolving GLP-1R agonist landscape — from GLP-1R monoagonists through dual agonists to Retatrutide’s triple agonism — has provided increasingly detailed characterization of what each additional receptor target contributes to the overall pharmacological profile. This comparative pharmacology research has practical implications for understanding which mechanistic components drive which physiological effects.
Studies comparing receptor binding kinetics, cAMP generation, and downstream signaling between Retatrutide and its predecessor compounds have characterized the differential potency ratios at each of the three receptor targets — an important parameter for interpreting which receptor is driving specific observed effects at any given dose in a research model.
The scientific rationale for triple receptor agonism requires understanding the distinct but interacting roles of GLP-1, GIP, and glucagon in metabolic physiology. GLP-1, released from intestinal L-cells following nutrient ingestion, drives insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety via central GLP-1R-expressing neurons. GIP, released from intestinal K-cells, provides a second incretin signal that enhances insulin secretion in a glucose-dependent manner and has direct effects on adipose tissue metabolism via GIPR expression on adipocytes.
Glucagon, released from pancreatic alpha cells in the fasted state, drives hepatic glucose production and fat oxidation — metabolic effects that appear counterproductive in the context of metabolic disease but that research has shown, when balanced against incretin activity, to enhance fat-specific energy expenditure without net glucose dysregulation. The therapeutic insight underlying Retatrutide’s design is that glucagon’s energy-mobilizing effects on adipose and hepatic tissue can be harnessed while its glycemic effects are neutralized by concurrent GLP-1R and GIPR agonism.
Research continues to examine whether this pharmacological balance can be optimized through potency ratio tuning at each receptor, and whether specific patient subpopulations — defined by metabolic phenotype, pancreatic function, or hepatic status — show differential responses to triple versus dual receptor agonism approaches.
Retatrutide’s fatty acid modification and large peptide structure require careful handling consistent with other long-acting incretin-based research peptides.
Reconstitution: Retatrutide reconstitutes in standard aqueous buffer. Gently swirl the vial — do not vortex — to avoid mechanical degradation of the peptide structure. Allow full dissolution before use and inspect for clarity before proceeding.
Storage after reconstitution: Maintain reconstituted Retatrutide at 4°C and use within 30 days. The fatty acid modification provides some protection against degradation, but prolonged storage in solution risks hydrolysis of the acyl chain and loss of albumin-binding capacity.
Glucagon receptor controls: Research designs examining Retatrutide must control for glucagon receptor-mediated effects, including potential increases in fasting blood glucose, hepatic glucose output, and heart rate. Vehicle and GLP-1R-only comparators are essential for isolating the specific contribution of GCGR agonism in mechanistic studies.
Species differences in receptor pharmacology: GLP-1R, GIPR, and GCGR pharmacology differs across species. Research findings in rodent models may not translate directly to primate biology — the GIP receptor in rodents, for example, has distinct signaling characteristics compared to the human receptor. Extrapolation of Retatrutide animal model data to human biology should be done with appropriate caution.
Official Peptides supplies research-grade Retatrutide at >99% purity verified by HPLC and mass spectrometry. As an actively investigated Phase III compound, Retatrutide represents one of the most current research interests in metabolic pharmacology, and we maintain consistent US-based inventory to support ongoing research programs. Batch-specific certificates of analysis are available for every purchase, and cold pack shipping ensures compound integrity during transit.
All content is provided for research reference purposes only. For in vitro laboratory research use only.